Compare MGPI & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGPI | EDIT |
|---|---|---|
| Founded | 1941 | 2013 |
| Country | United States | United States |
| Employees | 267 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.0M | 432.8M |
| IPO Year | 1994 | 2016 |
| Metric | MGPI | EDIT |
|---|---|---|
| Price | $17.13 | $2.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $28.75 | $5.30 |
| AVG Volume (30 Days) | 166.9K | ★ 2.7M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | N/A | ★ N/A |
| Revenue | $19,782,000.00 | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $15.72 | $1.66 |
| 52 Week High | $33.38 | $4.54 |
| Indicator | MGPI | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 51.01 |
| Support Level | $16.45 | $2.77 |
| Resistance Level | $20.67 | $3.27 |
| Average True Range (ATR) | 0.53 | 0.20 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 55.35 | 70.16 |
MGP Ingredients Inc is a producer and supplier of distilled spirits, specialty wheat protein, and starch food ingredients based in the United States. It operates in three reportable segments: Distillery Solutions, Branded Spirits Segment, and Ingredient Solutions. Maximum revenue is generated from the Branded Spirits segment, which consists of a portfolio of brands that it produces through its distilleries and bottling facilities and sells to distributors or to state governments that directly control the sale of alcohol. MGP's branded spirits include various brands across numerous categories and price tiers, such as Penelope Bourbon, Yellowstone Bourbon, Minor Case Straight Rye Whiskey, Brady's Irish Cream, Exotico Tequila, Arrow Cordials, Canada House Canadian Whisky, Lady Bligh Rum, etc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.